Shenzhen, China, March 29, 2023 - MGI signed a strategic agreement with Guangdong Hybribio Biotech Co., Ltd. (hereinafter referred to as "Hybribio"). The two parties have established a strategic partnership to expand the international market of gene sequencing technology. Based on MGI's DNBSEQ sequencing platform, Hybribio will develop precision medicine applications.

"Hybribio has intensively engaged in the field of molecular detection for more than 20 years. We have paid constant attention to the development and needs of the medical industry, and continually developed efficient, intelligent, and innovative solutions to make precision medicine services more accessible. We expect to join hands with MGI to promote the clinical application and development of high-throughput sequencing technology in maternal and child health, birth defects, infectious diseases, and tumors to improve human health with advanced technology and products." Said Guan Zhisheng, Hybribio Director & Executive Deputy General Manager.

"MGI has always focused on the innovation and R&D of life science core tools and technology to facilitate the industry development and improve human health. Based on the proprietary DNBSEQ technology, MGI has developed an extensive product portfolio covering low, medium, high and Ultra-high throughput to offer more options for global users. We expect to join hands with Hybribio to realize win-win cooperation, making more profound and comprehensive breakthroughs in the clinical application of high-throughput sequencing in precision medicine." Said Jiang Hui, COO of MGI.

As a vital cornerstone of precision medicine, high-throughput sequencing technology plays a significant role in clinically related pathogenic microorganism detection, early cancer screening, genetic disease detection, infectious disease monitoring, and the discovery of new viruses. As one of two companies in the world that can independently develop and mass-produce clinical gene sequencers, MGI has developed sequencing products for different application scenarios with industry-leading data output quality and competitive cost.

Hybribio is a leading nucleic acid molecular diagnosis product and service provider and a private medical laboratory group. Through this strategic cooperation, the two parties are expected to deepen their collaboration in facilitating the application of high-throughput sequencing platforms in genomics and precision medicine to empower maternal and child health, birth defects, infectious diseases, and tumors.